Mucoadhesive gel formulations help to increase the length of time a drug is present at the nasal absorption site, which helps to promote drug uptake. The goal of this work was to create a tripolyphosphate and chitosan-based thermosensitive in situ nanogel technology for the nasal delivery of dulaglutide, a GLP-1 drug. An ionic gelation method was used to make the nanogel containing dulaglutide. During formulation development, the components' concentrations were tuned, and the drug's loading, morphology, size, zeta potential, stability studies, and release behavior were all examined. Five mathematical models were fitted with the drug release data in order to determine which model best captured the phenomenon. Spectrophotometric analysis revealed that the in vitro release of dulaglutide from the gel network was sufficient to sustain blood glucose levels for a duration of 14 hours. Following the administration of the nano-formulation and the dulaglutide Sc injection as a control, rats' blood glucose levels and serum insulin levels were measured for antidiabetic action after 2, 4, 6, 8, and 10 hours. The findings from both in vitro and in vivo experiments suggest that the thermosensitive in situ gelling system that has been suggested has significant promise for use as a nasal delivery method for dulaglutide.